TABLE IV.
Meta-Analysis of Independent AMD-ApoE Association Studies in Caucasian Populations
| Control Allele no (%) |
AMD Allele no (%) |
OR (CI) | X2/P | Comments | ||
|---|---|---|---|---|---|---|
| Klaver et al. [1998a] | E2 | 162 (9.0) | 22 (12.5) | 1.44 (0.74–2.83) | 2.33/0.13 | Cases and controls derived from the population-based Rotterdam Study in the Netherlands. |
| E3 | 1,357 (75.3) | 142 (80.6) | ||||
| E4 | 281 (15.6) | 12 (6.8) | 0.39 (0.17–0.92) | 9.8/0.002 | ||
| Total | 1,800 | 176 | ||||
| Souied et al. [1998] | E2 | 21 (6.2) | 23 (9.9) | 1.65 (0.89–3.06) | 2.58/0.11 | Unrelated patients with exudative AMD compared to gender and age-matched controls. |
| E3 | 265 (78.9) | 192 (82.8) | ||||
| E4 | 50 (14.9) | 17 (7.3) | 0.45 (0.25–0.81) | 7.53/0.006 | ||
| Total | 336 | 232 | ||||
| Schmidt et al. [2000] | E2 | 60 (8.1) | 40 (8.7) | 1.09 (0.71–1.65) | 0.15/0.70 | Familial and sporadic cases of AMD were pooled as well as analyzed separately. Significant differences in age and gender at time of exam. However, estimated age/sex-adjusted ORs were made via logistic regression analysis. |
| E3 | 575 (77.3) | 366 (79.6) | ||||
| E4 | 109 (14.6) | 54 (11.7) | 0.77 (0.55–1.10) | 2.06/0.15 | ||
| Total | 744 | 460 | ||||
| Simonelli et al. [2001] | E2 | 2 (2) | 17 (9.8) | 5.20 (1.17–22.99) | 5.76/0.02 | Italian population, age-matched controls. |
| E3 | 89 (90.9) | 152 (87.3) | ||||
| E4 | 7 (7.1) | 5 (2.9) | 0.38 (0.12–1.25) | 2.71/0.10 | ||
| Total | 98 | 174 | ||||
| Schultz et al. [2003] | E2 | 56 (8.8) | 68 (9.4) | 1.08 (0.74–1.56) | 0.16/0.69 | Familial and unrelated AMD patients were included. Here, the groups are pooled. Trends of E4 in protection were found. |
| E3 | 497 (77.7) | 575 (79.2) | ||||
| E4 | 87 (13.6) | 83 (11.4) | 0.82 (0.59–1.13) | 1.46/0.23 | ||
| Total | 640 | 726 | ||||
| Baird et al. [2004] | E2 | 17 (6.9) | 50 (9.9) | 1.48 (0.84–2.63) | 1.84/0.17 | All participants were Anglo-Celtic in origin with all four grandparents born in either the UK or Ireland. |
| E3 | 185 (75.2) | 396 (78.6) | ||||
| E4 | 44 (17.9) | 58 (11.5) | 0.68 (0.44–1.03) | 3.84/0.05 | ||
| Total | 246 | 504 | ||||
| Zareparsi et al. [2004] | E2 | 33 (8.0) | 116 (9.2) | 1.16 (0.77–1.74) | 0.34/0.56 | White patient cohort recruited from a single center. Subsequent OR calculations were adjusted for both gender and age. |
| E3 | 320 (78.0) | 1,022 (81.2) | ||||
| E4 | 57 (14) | 120 (9.5) | 0.47 (0.33–0.66) | 4.78/0.03 | ||
| Total | 410 | 1,258 | ||||
| Current study | E2 | 46 (10.1) | 18 (5.6) | 0.89 (0.49–1.40) | 0.44/0.51 | Multiple case–control groups including advanced AMD cases only. |
| E3 | 327 (72.0) | 267 (83.5) | ||||
| E4 | 81 (17.9) | 35 (10.9) | 0.53 (0.33–0.80) | 7.4/0.007 | ||
| Total | 450 | 320 | ||||
| Pooled data | E2 | 397 (8.3) | 351 (9.1) | 1.11 (0.96–1.29) | 1.9/0.17 | |
| E3 | 3,615 (76.5) | 3,109 (80.8) | ||||
| E4 | 716 (15.2) | 390 (10.1) | 0.63 (0.55–0.71) | 48.4/0.000 | ||
| Total | 4,874 | 3,850 |